Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial.

Nian-di TanXiao-Wei LiuCheng-Xia LiuSheng-Bao LiHong-Hui ChenXing LiHao WuAi-Jun LiaoYan-Bo ZhenPeng-Zhen ShenLi-Juan HuoHong-Ling LiuRui-Hua ShiBing-Qiang ZhangZhen-Yu ZhangJian-Ning WangQiang ZhanHong DengXu ShuBi-Guang TuoQi-Zhi WangShi-Yu DuLing-Zhi QiGuo-Xin ZhangQiong PengBang-Mao WangBin YeMin-Hu ChenYing Lian Xiao

Published in: Journal of gastroenterology and hepatology (2022)

Keverprazan was effective and non-inferior to lansoprazole in healing DU. Based on the comparable efficacy and safety data, keverprazan of 20 mg once daily is recommended for the follow-up study of acid-related disorders. (Trial registration number: ChiCTR2100043455.).

Keyphrases

phase ii
double blind
placebo controlled
phase iii
clinical trial
open label
study protocol
electronic health record
physical activity
big data
randomized controlled trial
artificial intelligence
data analysis
deep learning